A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of once-daily intranasal administration of fluticasone furoate nasal spray 110mcg in adult and adolescent subjects 12 years of age and older with perennial allergic rhinitis (PAR).

Trial Profile

A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of once-daily intranasal administration of fluticasone furoate nasal spray 110mcg in adult and adolescent subjects 12 years of age and older with perennial allergic rhinitis (PAR).

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Fluticasone furoate (Primary)
  • Indications Perennial allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 05 Nov 2009 Results presented at the 2009 Annual Meeting of the American College of Allergy, Asthma and Immunology.
    • 27 Oct 2008 Actual end date (Jun 2008) added as reported by ClinicalTrials.gov.
    • 27 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top